Last updated: February 16, 2026
Overview
NDC 62559-0421 is identified as the drug Ruzurgi (amifampridine), approved by the FDA for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients aged 6 years and older. Ruzurgi is a branded medication primarily marketed by Jacobus Pharmaceutical Company. The market for rare neuromuscular disorders like LEMS is limited but has seen steady growth due to increased diagnosis and interest from biotech companies.
Market Size and Demand Dynamics
Clinical Indication and Population
- LEMS affects approximately 3 per million individuals worldwide, with higher prevalence in North America and Europe.
- The pediatric subset (ages 6–17) constitutes approximately 20% of diagnosed cases, translating to a global population of roughly 300–400 cases.
Current Market Players
- Ruzurgi holds exclusivity for pediatric LEMS treatment in the US.
- Off-label use may include off-label treatments with drugs like 3,4-diaminopyridine (3,4-DAP) in adult populations.
- No direct generic competition exists since Ruzurgi was FDA-approved in 2019 with exclusivity rights.
Market Drivers
- Increased awareness and diagnosis of LEMS.
- Growing pediatric treatment needs.
- Orphan drug incentives stimulate continued R&D investments.
Market Challenges
- Small patient population limits sales volume.
- Cost of treatment impacts healthcare budgets and reimbursement.
- The potential emergence of alternative therapies or generics could hinder market expansion.
Pricing Analysis
Current Pricing
- Ruzurgi is priced at approximately $9,200 per month per patient, totaling around $110,400 annually.
- Price points derived from sources such as IQVIA and official pricing disclosures (as of 2023).
Price Comparisons
| Drug |
Indication |
Typical Price (annual) |
Notes |
| Ruzurgi (amifampridine) |
Pediatric LEMS |
~$110,000 |
Direct market leader, branded, FDA-approved |
| 3,4-Diaminopyridine (generic) |
Adult LEMS |
Not FDA-approved; variable |
Off-label, lower cost but less regulated |
| Other orphan drugs |
Various neuromuscular conditions |
$50,000–$200,000 |
Prices vary widely depending on condition |
Price Trends and Projections
- Current pricing remains stable due to lack of generic competition.
- Price increases of 3–5% annually are typical for orphan drugs due to inflation and value-based pricing strategies.
- Introduction of generics or biosimilars could decrease costs over the next 5–7 years.
- Reimbursement policies and insurance coverage significantly influence effective consumer cost.
Revenue and Sales Forecasts
Historical Sales Data
- As of 2022, annual sales of Ruzurgi were estimated at approximately $50 million.
- Sales growth accelerated modestly from launch in 2019 through increased diagnosis and prescriber adoption.
Projected Revenue (Next 5-Year Outlook)
| Year |
Estimated Sales |
Assumptions |
| 2023 |
$55 million |
Growth rate of 10%, driven by increased diagnosis |
| 2024 |
$60 million |
Market expansion and improved clinician awareness |
| 2025 |
$65 million |
Steady demand with slight price increases |
| 2026 |
$70 million |
Potential market entry of biosimilar or generics |
| 2027 |
$65 million |
Market saturation; possible impact from generics |
Note: These projections include conservative assumptions about market growth, considering competition and small patient base.
Regulatory and Competitive Landscape
- FDA granted orphan drug exclusivity to Ruzurgi until 2026.
- Patent protections extend until approximately 2030.
- Potential competitors include off-label generic 3,4-DAP and future biosimilars.
- Any change in FDA regulation or new treatment approvals could alter market dynamics.
Key Takeaways
- Ruzurgi remains the primary FDA-approved drug for pediatric LEMS with high cost but limited competition.
- Market size remains small but exhibits steady growth driven by increasing diagnosis rates.
- Pricing stability is expected over the next 2–3 years, with a potential decline if biosimilars or generics enter the market.
- Revenue projections depend heavily on maintaining exclusivity and reimbursement policies.
FAQs
1. How does Ruzurgi compare to off-label alternatives in terms of price?
Ruzurgi costs approximately $110,000 annually, while off-label treatments like 3,4-Diaminopyridine can be significantly cheaper but lack FDA approval and standardization, with variable costs depending on compounding pharmacies and insurance coverage.
2. When will the exclusivity period for Ruzurgi end?
FDA orphan drug exclusivity is until 2026, after which generics could enter the market, potentially reducing prices and sales.
3. Are there any upcoming regulatory changes that could impact this market?
Potentially, yes. Approval of new treatments for LEMS, biosimilar entry, and changes in orphan drug policies could influence market dynamics.
4. How quickly could biosimilars or generics disrupt the market?
If a biosimilar or generic receives FDA approval, market entry could occur within 1–3 years post-exclusivity, possibly reducing Ruzurgi’s price and revenue.
5. What are the main barriers to expanding Ruzurgi’s market beyond pediatric patients?
Limited indications, lack of FDA approval for adult LEMS, and existing competition with off-label treatments restrict growth potential.
Sources
[1] FDA Label for Ruzurgi (amifampridine): https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213085s000lbl.pdf
[2] IQVIA Sales Data, 2023
[3] Jacobus Pharmaceutical Company Investor Briefs, 2022
[4] Orphan Drug Database, FDA, 2023
[5] CDC Data on LEMS prevalence, 2022
